The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of RRMM, with the goal to help guide real-world clinical practice and improve patient outcomes.
The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of patients with relapsed/refractory multiple myeloma (RRMM), which was published in the March 2021 issue of Lancet Oncology and summarized here.
Clinical considerations for patients with RRMM who have received 1 previous line of therapy, including whether the patient has lenalidomide-refractory disease and whether disease progression occurs with daratumumab-based regimens. Recommendations are below:
Recommendations for patients who are in second or higher relapse include:
These International Myeloma Working Group recommendations are expected to help guide real-world clinical practice with the goal of improving outcomes for patients with RRMM.
Source: Moreau P, Kumar SK, Miguel JS, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105-e118.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.